Head-to-head evidence
CT-P17 vs etanercept
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
CT-P17
Developed by Celltrion
NCT03789292 · Phase 3 · completed
The trial was a large randomized, quadruple-blind comparison of CT-P17 and Humira, with 324 participants per initial treatment group. Its primary clinical endpoint, ACR20 response at Week 24, had identical reported counts in both groups, but the registry does not state whether the prespecified statistical comparison met its criterion, so the result is unclear.
etanercept · Enbrel
Marketed by Amgen
NCT03780959 · Phase 2/3 · completed
After 90 days of open-label etanercept, 51 responding children were randomized to continue etanercept or receive placebo in a double-blind comparison. The clinical primary endpoint, disease flare, was met in favor of etanercept (28% vs 81% with placebo; p=0.0030), but the randomized sample was small, limiting the strength of the evidence.
Next expected readout: March 2028 · NCT03414502 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CT-P17's landscape · etanercept's landscape